Retatrutide and Knee Osteoarthritis in 2026: Two-Thirds of Patients Cut Their Knee Pain in Half in New Trials

The paper reports two randomized, double-blind, placebo-controlled trials — TRIUMPH-4 and TRIUMPH-1-OA — with more than 1,000 participants combined, all adults with moderate-to-severe knee osteoarthritis pain who were overweight or had obesity. TRIUMPH-4 enrolled 445 adults without diabetes who took 9 mg or 12 mg of retatrutide (or placebo) once weekly for 68 weeks. TRIUMPH-1-OA enrolled 574 participants on 4 mg, 9 mg, or 12 mg for 80 weeks. On average, participants started out weighing about 112 kg (around 247 pounds) with knee pain of roughly 6 on a 0-to-10 scale — pain that interferes with daily life.

After 68 weeks, knee pain scores fell by about 3.7 to 4 points on retatrutide in TRIUMPH-4, versus just over 2 points on placebo. In TRIUMPH-1-OA, pain dropped 3.2 to 3.6 points versus 1.9 on placebo. The most striking number came from the pooled analysis, reported by News-Medical's coverage of the NEJM paper: 63% to 70% of people on retatrutide achieved at least a 50% reduction in knee pain, compared with 38% on placebo. Physical function — things like walking, standing up, and using stairs — improved by a similar margin.

Retatrutide works on three hormone receptors at once — GLP-1, GIP, and glucagon — which is why it has posted some of the largest weight reductions ever seen in obesity trials. These knee studies were no exception. In TRIUMPH-4, participants lost 20% of their body weight on 9 mg and 23.7% on 12 mg, versus 4.6% on placebo. In TRIUMPH-1-OA, losses ranged from 17.5% on the lowest dose to 24.8% on 12 mg, versus 4.3% on placebo.

For the average participant, that's roughly 50 to 60 pounds. Every pound of body weight translates into about four pounds of force across the knee joint when you walk, so that kind of loss removes an enormous mechanical load from damaged cartilage. The researchers, led by Dr. Thomas Schnitzer of Northwestern University, believe reduced joint loading is the main driver, possibly along with an anti-inflammatory effect — though they're careful to note the mechanism isn't fully established.

Retatrutide is not FDA-approved, for weight loss or for arthritis, so you can't get it yet — and anything sold online as "reta" today is unregulated gray-market product that has already been linked to serious harm. But the idea that GLP-1 weight loss translates into joint relief isn't new. Semaglutide (the ingredient in Wegovy) showed meaningful knee osteoarthritis pain reduction in the STEP 9 trial, and the NEJM authors note the pain effect sizes in these retatrutide trials were larger than those historically reported for ibuprofen, tramadol, and even corticosteroid knee injections — though no head-to-head comparison exists, so those cross-trial contrasts should be read cautiously.

The practical takeaway: the medications available right now — semaglutide and tirzepatide, including higher-dose tirzepatide options — already produce 15% to 20%+ body weight loss for many patients, which is in the range where joint symptoms measurably improve. If knee pain is one of the reasons you're considering medical weight loss, you don't have to wait for retatrutide to act on that.

The trade-off showed up clearly at the higher doses. The most common side effects were gastrointestinal — nausea, diarrhea, and constipation — mostly mild to moderate and concentrated during dose escalation, the same pattern seen across the GLP-1 class (and one reason slower titration and anti-nausea support are standard parts of a well-managed program). About 15% to 18% of participants on the 12 mg dose stopped treatment because of side effects, versus roughly 4% to 6% on placebo. An unusual one for this class: up to about 21% reported dysesthesia — tingling or altered skin sensation — compared with under 1% on placebo.

There are also important limitations. The trials excluded people whose arthritis was severe enough to need knee replacement, didn't test whether the drug slows actual joint damage, and can't say whether the pain relief lasts after stopping. And like all GLP-1-class medications, these drugs aren't appropriate for everyone — a personal or family history of medullary thyroid cancer or MEN2, or a history of pancreatitis, are among the screening questions a licensed provider will walk through before prescribing anything in this class.

Osteoarthritis affects hundreds of millions of people, and weight is its single biggest modifiable risk factor — yet most treatment stops at painkillers and eventual surgery. These trials are the strongest evidence yet that treating the weight treats the knee. That doesn't make weight loss medication a replacement for physical therapy, strength work, or your rheumatologist's plan, and it's not a cure for arthritis. But it does mean that if you've been thinking of your knee pain and your weight as two separate problems, the research increasingly says they're one problem — and one that responds to treatment.

If you're ready to find out whether medical weight loss fits your situation, JoeyMed makes the process simple. Complete a short online health assessment, and a licensed provider will review your history — including joint symptoms, medications, and screening questions — and determine whether GLP-1 treatment such as semaglutide or tirzepatide is appropriate for you. If approved, your medication ships directly to your door, with ongoing provider support as your dose adjusts. Explore your options at JoeyMed Weight Loss and take the first step toward moving comfortably again.